The Securities and Exchange Commission may step up its scrutiny of drugmakers’ accounting practices, the agency announced in a letter to Allergan.

The SEC voiced its concerns over the practice of reporting company earnings through non-generally accepted accounting principles (GAAPs). If Allergan continues using this measure, the SEC wrote, the company’s officials should clarify how they present the data so their methods are not confused with GAAPs.